别名 DKFZp667A205、FLJ39873、T cell immunoreceptor with Ig and ITIM domains + [6] |
简介 Inhibitory receptor that plays a role in the modulation of immune responses. Suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells (PubMed:19011627). Upon binding to its ligands PVR/CD155 or NECTIN2/CD112, which are expressed on antigen-presenting cells, sends inhibitory signals to the T-cell or NK cell. Mechanistically, interaction with ligand leads to phosphorylation of the cytoplasmic tail by Src family tyrosine kinases such as FYN or LCK, allowing subsequent binding to adapter GRB2 and SHIP1/INPP5D. In turn, inhibits PI3K and MAPK signaling cascades (PubMed:23154388). In addition, associates with beta-arrestin-2/ARRB2 to recruit SHIP1/INPP5D that suppresses autoubiquitination of TRAF6 and subsequently inhibits NF-kappa-B signaling pathway (PubMed:24817116). Acts also as a receptor for NECTIN4 to inhibit NK cell cytotoxicity (PubMed:32503945). |
作用机制 PD-1抑制剂 [+1] |
在研机构 |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 TIGIT抑制剂 |
在研机构 |
原研机构 |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
作用机制 PD-1抑制剂 [+1] |
在研机构 |
原研机构 |
非在研适应症- |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2025-05-16 |
申办/合作机构 |
开始日期2025-05-07 |
申办/合作机构 |
开始日期2025-05-05 |
申办/合作机构 AstraZeneca AB [+1] |